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pregnancy outcomes. Methods: To determine whether additional clinical tests, 
advice, planning, management or pregnancy follow-up were recommended for 
obese women during pregnancy,Clinical Practice Guidelines (CPGs) were collated 
from across the Endocrinology and Obstetrics National Societies websites of 
the 9 European countries participating in the FP7 DALI study (Austria, Belgium, 
Denmark, Ireland, Italy, The Netherlands, Poland, Spain, UK). This was comple-
mented by a Medline search and a survey among the investigators of the DALI 
study. Results: Fifteen CPG for 9 countries were retrieved. All but Spanish guide-
lines, which recommend O’Sullivan test, recommend OGTT 75g to detect GDM in 
obese women. Most of them include 24-28 weeks as the time for OGTT, but other 
schedules are also used, especially when risk factors other than obesity are pre-
sent. Other common recommendations for obese women in European CPGs were 
diet advice (included in the guidelines of 6 different countries), special birth plan-
ning (5 countries), exercise and other lifestyle recommendations (4 countries) and 
vitamin D supplementation, multidisciplinary follow-up (including endocrinolo-
gist or diabetologist) and additional ultrasound scan (3 countries). ConClusions: 
Recommendations for obese women in the studied countries are heterogeneous 
and in many cases do not include actions beyond screening for GDM. Existing 
guidelines will be reviewed in the light of the findings from the interventions 
studied in the framework of the DALI study.
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objeCtives: Infertility affects 14% of couples in reproductive age in Spain. 
Progressive population ageing leads the assessment of policies that favor birth-
rates. The objective is estimating the lifetime economic benefits of publicly 
financing assisted reproductive therapies (ART) in Spain, by calculating the 
return on this investment. Methods: Generational accounting model that 
simulates the flow of taxes paid by the individual minus those direct govern-
ment transfers received (e.g. health care, education, pensions) over the lifecycle 
of a child. The cost of ART was calculated as the average cost of conceiving a 
child through currently available ART in Spain. The difference between dis-
counted transfers and taxes minus the cost of ART equals the net present value 
(NPV) of a child conceived by ART. Year 2006 was set as the base case because 
of its macroeconomic stability. A 3.5% discount rate was applied. Sensitivity 
analysis tested robustness of results under different scenarios. Results: An 
ART-conceived child would contribute € 534,624 in net taxes to the government 
and would receive € 479,952 in governmental transfers over her lifecycle. After 
discounting the cost of ART (9,000€ ) the NPV is estimated at € 45,672. Each Euro 
invested in subsidizing ART reverts into fiscal benefits of € 5. Sensitivity analy-
sis shows that even in extreme macroeconomic scenarios, the long-run NPV 
of an ART-conceived child ranges between € 11,233 and € 62,470. The return on 
investment varies between € 1.25 y € 6.94 € for each Euro invested in ART. The 
break-even age at which the financial position begins to be favorable to the 
Spanish Treasury was set at 34-42 years. ConClusions: Generational account-
ing models allow estimating long-term fiscal implications of public funding of 
ART. Each Euro invested in subsidizing ART reverts into fiscal benefits of € 5. 
Thus, investment in ART leads to substantial discounted future fiscal revenue 
for the Spanish Treasury, notwithstanding its beneficial psychological effect 
for infertile couples.
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objeCtives: The new German law AMNOG was introduced in 2011. According to 
it all newly launched therapy options would need to be evaluated by the Institute 
for Quality and Efficiency in health care (IQWIG) and the joint federal committee 
(Gemeinsamer Bundesausschuss, GBA) before a final price negotiation will happen. 
Given the specific characteristics of pediatric patients it is uncertain if a new drug 
for those patients would successfully pass the AMNOG process. Methods: The 
AMNOG evaluation criteria were applied to the specifics of pediatric drugs. A special 
focus was given to the benefit assessment method, clinical trial designs and the 
AMNOG process. Results: Current HTA evaluation methods being applied to medi-
cal therapies, in general, need to be modified when applied to pediatric therapies. 
For example, traditional benefit evaluations that require randomized clinical trials 
are standard but cannot always be fulfilled in this patient population. In pediatric 
development programs one-arm studies are standard with surrogate endpoints in 
order to minimize the exposure of children to an experimental therapy. Additionally 
the naturally low sample size within pediatric indications linked to the different 
natural subgroups of children (babys, toddlers, etc.) make a formal additional ben-
efit proof even harder. Hence from a benefit assessment perspective the clinical 
study design, sample size and choice of endpoint are most crucial but could hardly 
be executed in pediatric trials. With respect to the AMNOG process only pediatric 
trials in orphan disease could pass successfully given the exception rules for the 
additional benefit. ConClusions: If the German health care system is to secure 
the full benefits of potential new pediatric therapies, it will need to provide a similar 
process as it is granted for orphan drugs.
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an acute condition (acute tonsillitis in an 8 year old child) and a chronic condition 
(an adult with diabetes mellitus type 2) was developed. WTP for a BD as compared 
with a GD was assessed in both scenarios using the payment scale and the open-
ended formats. The study was approved by the local ethical committee. Results: 
Respondents were predominantly women (57%) and the mean age was 54 y.o. A 
family income of less than R$ 1.356,00 was reported by 16%. For the total study 
sample, the maximum WTP for a BD (over and above the mean retail price of a GD) 
for the acute and chronic case scenarios were on average R$ 27,54 and R$ 21,04 
when measured by the payment scale and R$ 36,54 and R$ 24,77 when measured 
by the open-ended question, respectively. These values are 36% to 65% above the 
mean retail prices of the corresponding GD. ConClusions: Patients and accom-
panying persons were willing to pay considerably more for the BD when compared 
to GD. This may be driven by the perception of higher perceived effectiveness and 
safety of BD.
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objeCtives: To assess which of the studied factors were positively associated with 
the students’ health and to investigate which of these factors stood out as the most 
important protective factors for their health. Methods: Data were obtained from 
a cross-sectional study conducted during the academic 2011/2012th at the universi-
ties in Niš, Belgrade and Novi Sad, which surveyed a total of 2285 students of both 
sexes. This study examines variables such as physical, psychological and social 
health, protective factors and risk factors. Students were assessing their own health 
answering the questionnaire. Results: Only 11.8% of the surveyed students have 
assessed their health as excellent, 72.5% as very good or good, and 15.7% as poor or 
very poor. Better health status was positively correlated with the quality of sleep, 
the existence of free time, physical and social activities, religiosity and built health 
values in all three universities. Kruskal-Wallis H test showed that better students are 
more satisfied with their life (p < 0.001), that better assess their health (p < 0.01) and 
less drink alcoholic beverages. Female students had more physical pain, were more 
frequently depressed than men, they were more easily tired, they were much more 
nervous and had more problems than men with sleep. Men assessed their health as 
better than female students. However, the satisfaction scale (χ 2 homogeneity test; 
p < 0.001) were found females to be more satisfied with their lives than male stu-
dents. ConClusions: General health is affected by various physical, psychological 
and social aspects of health. The results show that there are significant protective 
factors for better social, psychological and general health in students that may be 
affected. Therefore, health promotion decision makers should adopt contemporary 
strategies that will in the future put emphasis on the social and psychological 
components of students’ health.
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objeCtives: Uterine fibroids (UF) affect approximately 20% to 40% of repro-
ductive-aged women. The mainstay of treatment of symptomatic UF is surgical. 
Myomectomy surgically removes UF while preserving the uterus. However, hyster-
ectomy that is considered to be the definitive treatment of UF, causes infertility.The 
aim of our study was to analyze the prevalence of hysterectomy in Hungary among 
reproductive-aged women with UF to assess the societal burden due to lost fertil-
ity. Methods: Database were analyzed. Surgical procedures for the treatment of 
UF (ICD-10: D25), in 20-45 years old women between 2007 and 2012 were analyzed 
based on the Hungarian National Health Insurance Fund database. Economic bur-
den of lost fertility was assessed by the human capital approach. Present value of 
life for a newborn child was calculated by applying 2011 GDP per capita and 3.7% 
discount rate. Results: Among 11,095 women with surgical procedure related 
to UF the prevalence of hysterectomy was 61.5% (n= 6827). Most hysterectomised 
women (n= 4781) were 40-45 years old; unexpectedly a significant number of 20-40 
years old women with UF had hysterectomy (n= 2046). Present value of a newborn 
child was 262,314 EUR in 2011. ConClusions: Our results indicate that immediate 
hysterectomy, even in women under 40 years, is still a frequently performed surgi-
cal procedure for the treatment of UF. The macroeconomic consequences of lost 
fertility due to hysterectomy in reproductive-aged women with UF are significant. 
Even only one additional child-birth due to avoided hysterectomy would result in 
significant societal and economic benefits. Further scientific evaluations are needed 
to define more accurately the long term macroeconomic impact of preserved fertil-
ity in women with UF.
PIH54
managemenT oF oBese Women durIng Pregnancy across euroPe 
accordIng To cLInIcaL PracTIce guIdeLInes
Callejo D.1, Díaz-Cuervo H.1, Fernández-Ortiz L.1, Rebollo P.1, Simmons D.2, van Poppel M.3
1LASER Analytica, Oviedo, Spain, 2Addenbrooke’s Hospital, Cambridge, UK, 3VUmc, Amsterdam, 
The Netherlands
objeCtives: To review, within the framework of the FP7 DALI (Vitamin D And 
Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention) study, 
guidelines for the management of obese women during pregnancy across Europe 
to assess the specificity of the recommendations in this group at risk of adverse 
